Zydus Therapeutics' saroglitazar drug granted priority review by US FDA

Zydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver disease. The company plans to launch saroglitazar in the US in the fourth quarter of fiscal year 2027.

Raccontata daeconomictimes.indiatimes.com